Welcome to the e-CCO Library!

P414 Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Khoo1, A. Lord2, K. Hanigan1, A. Croft1, G. Radford-Smith1,2

Created: Thursday, 30 January 2020, 10:12 AM
P414: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Atreya, R.(10);Teich, N.(11);Trentmann, L.(12);Ehehalt, R.(13);Franzenburg, S.(3);Hartmann, P.(4);di Giuseppe, R.(3);Schreiber, S.(2,3);
Created: Friday, 14 July 2023, 11:05 AM
P414: Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Sousa*, A.P. Silva, A. Rodrigues, J. Rodrigues, J. Silva, C. Gomes, L. Proença, J. Carvalho

Created: Thursday, 21 February 2019, 9:14 AM
P414: Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P414: Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity
Year: 2022
Source: ECCO'22
Authors: Bianchi, R.(1);Von Känel, R.(2);Roth, R.(3);Schreiner, P.(1);Rossel, J.B.(4);Barry, M.P.(4);Dora, B.(1);Kloth, P.(1);Juillerat, P.(5);Greuter, T.(6);Misselwitz, B.(5);Schoepfer, A.(6);Scharl, M.(1);Rogler, G.(1);Biedermann, L.(1);
Created: Friday, 11 February 2022, 3:52 PM
P414: Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Murakami*1, T. Kanemura1, A. Haga1, R. Kubota1, K. Yaguchi1, M. Nishio1, S. Tsuda1, T. Ogashiwa1, Y. Kogure1, K. Kasahara1, K. Hirai2, Y. Fukuno2, M. Jin2, A. Hanzawa2, H. Yonezawa2, K. Sakamaki3, K. Numata4, H. Kimura1, R. Kunisaki1

Created: Friday, 22 February 2019, 9:49 AM
P414: Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. W. M. Pauwels*1, A. C. de Vries1, J. C. Goet1, N. S. Erler2, C. J. van der Woude1

Created: Friday, 22 February 2019, 9:41 AM
P414: Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ledder O.*1, de Meij T.2, Martín de Carpi J.3, Richmond L.4, Cohen S.5, Bronsky J.6, Shaoul R.7, Levine A.8, Escher J.9, deRidder L.9, Assa A.10, Ruemmele F.11, Shah N.12, Wolters V.13, Rodrigues A.14, Uhlig H.14, Urlep D.15, Posovsky C.16, Kolho K.17, Turner D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Gubbiotti1, B. Barberio1, F. Zingone1, R. D’Incà1, L. Bertani2, A. Ferronato3, M.T. Urbano4, R. Sablich4, E.V. Savarino1

Created: Thursday, 30 January 2020, 10:12 AM
P415: Dose escalation of adalimumab and related prognostic factors in patients with Crohn's disease treated with adalimumab maintenance therapy: A single-centre, five-year cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Nasuno*, H. Tanaka, K. Sugiyama, M. Miyakawa, S. Motoya

Created: Thursday, 21 February 2019, 9:14 AM
P415: Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial
Year: 2022
Source: ECCO'22
Authors: Cox, S.(1);Wall, C.(2);Clarke, H.(1);Drysdale, C.(1);Czuber-Dochan, W.(3);Lomer, M.(1);Lindsay, J.(4);Whelan, K.(1);
Created: Friday, 11 February 2022, 3:52 PM
P415: Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents
Year: 2021
Source: ECCO'21 Virtual
Authors: Matsune, Y.(1);Kouyama, J.(1);Tsuru, Y.(1);Shimizu, K.(1);Asami, S.(1);Matsuyama, S.(1);Katsuki, S.(1);Ishihara, H.(1);Onizawa, R.(1);Shonai, S.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Takeuchi, K.(1);Watanabe, M.(1);Nakamori, Y.(1);Hirayama, A.(1);Toyoda, J.(1);Ikeda, A.(1);Madarame, A.(1);Nishio, M.(1);Ogashiwa, T.(1);Matsubayashi, M.(1);Fujii, A.(1);Kimura, H.(1);Kunisaki, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Rivière1, A. Malian1, D. Bouchard2, F. Pigot2, M. Eleouet-Kaplan2, C. Favreau-Weltzer2, F. Poullenot1, D. Laharie1

Created: Friday, 22 February 2019, 9:41 AM
P415: Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Stallmach, A.(1)*;Schulze, H.(2);Teich, N.(3);Cavlar, T.(4);Jana, K.(4);Henneberger, S.(5);
Created: Friday, 14 July 2023, 11:05 AM
P415: Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. N. W. Chuah*1, P. Delord2, N. Sutiman3, W. F. Leong3, S. C. Kong1, B. Schwender1, P. W. Chan1, H. H. Shim1, E. Salazar1, E. H. Ong4, H. Y. Aw5, J. L. Hartono4, W. C. Lim6, C. Ong7, P. L. Ong8, K. L. Ling1, B. Chowbay2

Created: Friday, 22 February 2019, 9:49 AM
P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Narula N.*1, Borges L.2, Steinhart A.H.3, Colombel J.-F.4

Created: Wednesday, 20 February 2019, 10:36 AM
P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Pai2, J. Popov3, L. Hill4, E. Hartung1, K. Grzywacz5, D. Godin5, L. Thabane6, C. Lee7, W. Khan7, M. Surette2,8,9, P. Moayyedi2,8

Created: Thursday, 30 January 2020, 10:12 AM
P416: Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Poredska, K.(1);Kunovský, L.(2);Marek, F.(2);Kala, Z.(2);Ivanecká, D.(2);Iesalnieks, I.(3);
Created: Friday, 11 February 2022, 3:52 PM
P416: An online educational portal is effective in improving knowledge regarding reproduction and IBD
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Wierstra1, K. Smith1, J. Bal2, L. Ambrosio2, K. I. Kroeker2, L. Dieleman2, B. Halloran2, R. N. Fedorak2, K.-A. Berga3, V. W. Huang*4

Created: Friday, 22 February 2019, 9:49 AM
P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Bertani*1, L. Ceccarelli2, M. G. Mumolo2, R. Tedeschi1, E. Albano1, G. Tapete1, G. Baiano Svizzero1, N. De Bortoli1, A. Ricchiuti2, M. Bellini1, S. Marchi1, F. Costa2

Created: Friday, 22 February 2019, 9:41 AM